Yumanity Therapeutics, Inc. to sell its clinical-stage product candidate YTX-7739 as well as its unpartnered discovery-stage neuroscience product candidates and targets to Janssen Pharmaceutica NV in a $26 million cash transaction
Kineta, Inc., a private immuno-oncology company, to merge with Yumanity in an all-stock transaction that will advance Kineta’s potential best-in-class VISTA blocking immunotherapy
The combined company expects to close a PIPE financing in connection with the proposed merger
Yumanity and Kineta to host webcast today at 8:30 a.m. EDT
Yumanity and Kineta will host a webcast today, June 06, 2022, at 8:30 a.m. EDT to discuss the proposed merger with Kineta. The conference call may be accessed at https://www.yumanity.com/investor-relations/events-presentations/.
https://finance.yahoo.com/news/yumanity-therapeutics-announces-definitive-agreements-103000748.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.